

North Central Cancer Treatment Group

N0177: A Phase I/II Trial of OSI-774 and Temozolomide in Combination with Radiation Therapy in Glioblastoma Multiforme

Status Change – April 10, 2007

**NOTICE OF STATUS CHANGE**

**Study 2** is temporarily closed effective Wednesday, April 10, 2007. Accrual to dose level 3ER (OSI-774 at 500 mg) has been met.

**Please retain this notice with the protocol.**